Francesco Lapi, Ettore Marconi, Iacopo Cricelli, Alessandro Rossi, Tecla Mastronuzzi, Giovanni Gabutti, Claudio Cricelli
Background: In recent years, Europe has experienced a significant increase in pertussis cases. One reason behind this rise is the decline in diphtheria-tetanus-pertussis (dTap) booster coverage among adults. Currently, Italy lacks a reliable monitoring system to track pertussis infections and vaccine coverage among adults. We therefore evaluated the reliability of a primary care framework to respond to this need. Methods: Using an Italian primary care database for individuals aged 15 or above, we determined the pertussis infection notification rate and dTap vaccine/booster coverage for the timeframe of 2009-2022. Results: In the overall population, we obtained a lifetime occurrence rate of pertussis infections of 7.52 per 10,000 individuals. The annual incidence rates of pertussis infections ranged from 0.008 to 0.001 per 10,000 person-years between 2009 and 2022. A rising trend in dTap vaccine coverage rate (ranging from 8.72 to 16.54 vaccines per 10,000 individuals) was observed during the same period. Notably, those aged 65 or older, smokers, and/or individuals with immunodeficiencies were more likely to receive the dTap vaccine compared to the general population. Conclusions: Given the organization of the Italian public health system, this primary care network might act as a reliable epidemiological monitoring system to keep track of pertussis infections and dTap vaccine coverage in adults. Pertussis cases were underreported, and there was a low uptake of vaccines and boosters. Therefore, it is crucial to closely monitor pertussis notifications and dTap administrations and develop intervention strategies at the national level to enhance vaccine-related prevention.
{"title":"Pertussis Notification Rate and Tdpa Vaccine/Booster Coverage in Adults: An Opportunity for an Epidemiological Observatory in Primary Care.","authors":"Francesco Lapi, Ettore Marconi, Iacopo Cricelli, Alessandro Rossi, Tecla Mastronuzzi, Giovanni Gabutti, Claudio Cricelli","doi":"10.3390/idr16050068","DOIUrl":"10.3390/idr16050068","url":null,"abstract":"<p><p><b>Background</b>: In recent years, Europe has experienced a significant increase in pertussis cases. One reason behind this rise is the decline in diphtheria-tetanus-pertussis (dTap) booster coverage among adults. Currently, Italy lacks a reliable monitoring system to track pertussis infections and vaccine coverage among adults. We therefore evaluated the reliability of a primary care framework to respond to this need. <b>Methods</b>: Using an Italian primary care database for individuals aged 15 or above, we determined the pertussis infection notification rate and dTap vaccine/booster coverage for the timeframe of 2009-2022. <b>Results</b>: In the overall population, we obtained a lifetime occurrence rate of pertussis infections of 7.52 per 10,000 individuals. The annual incidence rates of pertussis infections ranged from 0.008 to 0.001 per 10,000 person-years between 2009 and 2022. A rising trend in dTap vaccine coverage rate (ranging from 8.72 to 16.54 vaccines per 10,000 individuals) was observed during the same period. Notably, those aged 65 or older, smokers, and/or individuals with immunodeficiencies were more likely to receive the dTap vaccine compared to the general population. <b>Conclusions</b>: Given the organization of the Italian public health system, this primary care network might act as a reliable epidemiological monitoring system to keep track of pertussis infections and dTap vaccine coverage in adults. Pertussis cases were underreported, and there was a low uptake of vaccines and boosters. Therefore, it is crucial to closely monitor pertussis notifications and dTap administrations and develop intervention strategies at the national level to enhance vaccine-related prevention.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"870-879"},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michele Salvatore Paternò Raddusa, Andrea Marino, Benedetto Maurizio Celesia, Serena Spampinato, Carmen Giarratana, Emmanuele Venanzi Rullo, Bruno Cacopardo, Giuseppe Nunnari
The intersection of Human Immunodeficiency Virus (HIV) infection and cardiovascular disease (CVD) represents a significant area of concern; advancements in antiretroviral therapy (ART) have notably extended the life expectancy of people living with HIV (PLWH), concurrently elevating the prevalence of chronic conditions such as CVD. This paper explores the multifaceted relationship between HIV infection, ART, and cardiovascular health, focusing on the mechanisms by which HIV and ART contribute to increased cardiovascular risk, including the promotion of endothelial dysfunction, inflammation, immune activation, and metabolic disturbances. We highlight the critical roles of HIV-associated proteins-Tat, Nef, and gp120-in accelerating atherosclerosis through direct and indirect pathways that exacerbate endothelial damage and inflammation. Additionally, we address the persistent challenge of chronic inflammation and immune activation in PLWH, factors that are strongly predictive of non-AIDS-related diseases, including CVD, even in the context of effective viral suppression. The impact of ART on cardiovascular risk is examined, with particular attention to the metabolic implications of specific ART regimens, which can influence lipid profiles and body composition, thereby modifying CVD risk. The therapeutic potential of statins, aspirin, and emerging treatments such as PCSK9 inhibitors in mitigating cardiovascular morbidity and mortality among PLWH is discussed, alongside considerations for their use in conjunction with ART. Our review underscores the necessity for a comprehensive, multidisciplinary approach to cardiovascular care in PLWH, which integrates vigilant cardiovascular risk assessment and management with HIV treatment. As we navigate the evolving landscape of HIV care, the goal remains to optimize treatment outcomes while minimizing cardiovascular risk, ensuring that the gains in longevity afforded by ART translate into improved overall health and quality of life for PLWH.
人类免疫缺陷病毒(HIV)感染与心血管疾病(CVD)的交叉是一个值得关注的重要领域;抗逆转录病毒疗法(ART)的进步显著延长了 HIV 感染者(PLWH)的预期寿命,同时也提高了心血管疾病等慢性疾病的发病率。本文探讨了艾滋病病毒感染、抗逆转录病毒疗法和心血管健康之间的多方面关系,重点关注艾滋病病毒和抗逆转录病毒疗法导致心血管风险增加的机制,包括促进内皮功能障碍、炎症、免疫激活和代谢紊乱。我们强调了 HIV 相关蛋白--Tat、Nef 和 gp120 的关键作用,它们通过直接和间接途径加剧了内皮损伤和炎症,从而加速了动脉粥样硬化。此外,我们还探讨了艾滋病毒感染者中长期存在的慢性炎症和免疫激活问题,即使在病毒得到有效抑制的情况下,这些因素仍可强烈预测包括心血管疾病在内的非艾滋病相关疾病。研究探讨了抗逆转录病毒疗法对心血管疾病风险的影响,尤其关注特定抗逆转录病毒疗法对代谢的影响,这些疗法会影响血脂状况和身体组成,从而改变心血管疾病风险。文章讨论了他汀类药物、阿司匹林以及 PCSK9 抑制剂等新兴治疗方法在降低 PLWH 心血管疾病发病率和死亡率方面的治疗潜力,以及将这些药物与抗逆转录病毒疗法结合使用的注意事项。我们的综述强调了对 PLWH 的心血管治疗采取全面、多学科方法的必要性,这种方法将警惕性心血管风险评估和管理与 HIV 治疗相结合。在不断发展的艾滋病治疗过程中,我们的目标仍然是在优化治疗效果的同时最大限度地降低心血管风险,确保抗逆转录病毒疗法带来的长寿效应转化为艾滋病感染者整体健康水平和生活质量的提高。
{"title":"Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review.","authors":"Michele Salvatore Paternò Raddusa, Andrea Marino, Benedetto Maurizio Celesia, Serena Spampinato, Carmen Giarratana, Emmanuele Venanzi Rullo, Bruno Cacopardo, Giuseppe Nunnari","doi":"10.3390/idr16050066","DOIUrl":"10.3390/idr16050066","url":null,"abstract":"<p><p>The intersection of Human Immunodeficiency Virus (HIV) infection and cardiovascular disease (CVD) represents a significant area of concern; advancements in antiretroviral therapy (ART) have notably extended the life expectancy of people living with HIV (PLWH), concurrently elevating the prevalence of chronic conditions such as CVD. This paper explores the multifaceted relationship between HIV infection, ART, and cardiovascular health, focusing on the mechanisms by which HIV and ART contribute to increased cardiovascular risk, including the promotion of endothelial dysfunction, inflammation, immune activation, and metabolic disturbances. We highlight the critical roles of HIV-associated proteins-Tat, Nef, and gp120-in accelerating atherosclerosis through direct and indirect pathways that exacerbate endothelial damage and inflammation. Additionally, we address the persistent challenge of chronic inflammation and immune activation in PLWH, factors that are strongly predictive of non-AIDS-related diseases, including CVD, even in the context of effective viral suppression. The impact of ART on cardiovascular risk is examined, with particular attention to the metabolic implications of specific ART regimens, which can influence lipid profiles and body composition, thereby modifying CVD risk. The therapeutic potential of statins, aspirin, and emerging treatments such as PCSK9 inhibitors in mitigating cardiovascular morbidity and mortality among PLWH is discussed, alongside considerations for their use in conjunction with ART. Our review underscores the necessity for a comprehensive, multidisciplinary approach to cardiovascular care in PLWH, which integrates vigilant cardiovascular risk assessment and management with HIV treatment. As we navigate the evolving landscape of HIV care, the goal remains to optimize treatment outcomes while minimizing cardiovascular risk, ensuring that the gains in longevity afforded by ART translate into improved overall health and quality of life for PLWH.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"846-863"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jan Rožanec, Natalija Kranjec, Ivana Obid, Andrej Steyer, Tjaša Cerar Kišek, Tom Koritnik, Mario Fafangel, An Galičič
Since COVID-19, mpox was the first emerging pathogen to have spread globally in 2022. Wastewater-based surveillance (WBS) has proven to be an efficient early warning system for detecting potential resurgences. This report aims to provide insight into the development and implementation of WBS of mpox in Slovenia and to incorporate the surveillance results into the development of public health interventions. WBS of mpox was conducted during the period from 1 June 2023 to 30 September 2023 at the wastewater treatment plant (WWTP) Ljubljana and WWTP Koper. The selected detection method of the monkeypox virus (MPXV) in the wastewater sample was based on PCR analysis. The implemented laboratory method showed that the sample preparation and concentration method enables a stable procedure for MPXV detection in wastewater samples. The laboratory analysis of wastewater samples from the selected WWTPs did not detect the MPXV during the monitoring period. In the event of MPXV detection in a wastewater sample, targeted public health interventions would be implemented, focusing on increasing awareness among the groups of men who have sex with other men and searching for positive mpox cases. We recommend that the developed system be retained in the case of an emergency epidemiological situation.
{"title":"Wastewater Surveillance of Mpox during the Summer Season of 2023 in Slovenia.","authors":"Jan Rožanec, Natalija Kranjec, Ivana Obid, Andrej Steyer, Tjaša Cerar Kišek, Tom Koritnik, Mario Fafangel, An Galičič","doi":"10.3390/idr16050065","DOIUrl":"10.3390/idr16050065","url":null,"abstract":"<p><p>Since COVID-19, mpox was the first emerging pathogen to have spread globally in 2022. Wastewater-based surveillance (WBS) has proven to be an efficient early warning system for detecting potential resurgences. This report aims to provide insight into the development and implementation of WBS of mpox in Slovenia and to incorporate the surveillance results into the development of public health interventions. WBS of mpox was conducted during the period from 1 June 2023 to 30 September 2023 at the wastewater treatment plant (WWTP) Ljubljana and WWTP Koper. The selected detection method of the monkeypox virus (MPXV) in the wastewater sample was based on PCR analysis. The implemented laboratory method showed that the sample preparation and concentration method enables a stable procedure for MPXV detection in wastewater samples. The laboratory analysis of wastewater samples from the selected WWTPs did not detect the MPXV during the monitoring period. In the event of MPXV detection in a wastewater sample, targeted public health interventions would be implemented, focusing on increasing awareness among the groups of men who have sex with other men and searching for positive mpox cases. We recommend that the developed system be retained in the case of an emergency epidemiological situation.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"836-845"},"PeriodicalIF":3.4,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marco Moretti, Julien Van Nedervelde, Robin Vanstokstraeten, Lucie Seyler, Fedoua Echahidi, Benoit Prevost, Delphine Martiny, Ingrid Wybo, Charlotte Michel
Background: The incidence of Legionnaires' disease (LD) is increasing steadily in Europe. Its early diagnosis by general practitioners (GPs) is crucial for better patient outcomes. Study objectives: This study assessed Belgian GPs' knowledge about LD and the accessibility of diagnostic tests in their practices. Methods: A specifically designed questionnaire was distributed to actively practicing GPs, including primary care trainees, between 31 January 2022 and 13 March 2022. This survey targeted approximately 4200 GPs with an estimated population catchment of 30% of the actively working Belgian GPs. Results: The response rate was estimated at 3%. Over 70% of the GPs correctly identified the LD occurrence peak, major risk factors, and clinical manifestations. While 62% of participants preferred the Legionella pneumophila urinary antigen test (UAT) as a primary diagnostic method, 75% were unsure about its availability within their laboratories and 82% had not prescribed it in the last year. Finally, 76% expressed a desire for additional information on this topic. Conclusions: Belgian GPs should evaluate the possibility of conducting UAT testing in their laboratories to enhance LD case management and improve their preparedness. Furthermore, initiatives should be implemented to improve communication between specialists and GPs and develop educational programs directed at Belgian GPs.
{"title":"Uncovering Gaps in Knowledge: A Survey of Belgian General Practitioners' Awareness of Legionnaires' Disease Diagnostic Testing.","authors":"Marco Moretti, Julien Van Nedervelde, Robin Vanstokstraeten, Lucie Seyler, Fedoua Echahidi, Benoit Prevost, Delphine Martiny, Ingrid Wybo, Charlotte Michel","doi":"10.3390/idr16050063","DOIUrl":"10.3390/idr16050063","url":null,"abstract":"<p><p><b><i>Background</i>:</b> The incidence of Legionnaires' disease (LD) is increasing steadily in Europe. Its early diagnosis by general practitioners (GPs) is crucial for better patient outcomes. <b><i>Study objectives</i>:</b> This study assessed Belgian GPs' knowledge about LD and the accessibility of diagnostic tests in their practices. <b><i>Methods</i>:</b> A specifically designed questionnaire was distributed to actively practicing GPs, including primary care trainees, between 31 January 2022 and 13 March 2022. This survey targeted approximately 4200 GPs with an estimated population catchment of 30% of the actively working Belgian GPs. <b><i>Results</i>:</b> The response rate was estimated at 3%. Over 70% of the GPs correctly identified the LD occurrence peak, major risk factors, and clinical manifestations. While 62% of participants preferred the <i>Legionella pneumophila</i> urinary antigen test (UAT) as a primary diagnostic method, 75% were unsure about its availability within their laboratories and 82% had not prescribed it in the last year. Finally, 76% expressed a desire for additional information on this topic. <b><i>Conclusions</i>:</b> Belgian GPs should evaluate the possibility of conducting UAT testing in their laboratories to enhance LD case management and improve their preparedness. Furthermore, initiatives should be implemented to improve communication between specialists and GPs and develop educational programs directed at Belgian GPs.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"820-827"},"PeriodicalIF":3.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlo Pallotto, Andrea Tommasi, Elisabetta Svizzeretto, Giovanni Genga, Giulia Gamboni, Anna Gidari, Daniela Francisci
Background: Pseudomonas aeruginosa is one of the major concerns among bacterial diseases even when it shows a wild-type susceptibility pattern. In 2020, EUCAST reconsidered antibiogram interpretation shifting "I" from "intermediate" to "sensible, increased exposure" with possible significant impact on antibiotic prescription. The aim of this study was to evaluate mortality in patients with P. aeruginosa bloodstream infections treated with antipseudomonal penicillins or cephalosporins vs. carbapenems and ceftazidime/avibactam.
Methods: This is a retrospective observational study. All the patients with a bloodstream infection due to P. aeruginosa admitted to our hospital were enrolled. Exclusion criteria were as follows: extremely critical conditions, age <18 years, pregnancy, isolation of a strain non-susceptible to piperacillin/tazobactam and antipseudomonal cephalosporins. Patients were divided into group A (treatment with carbapenems or ceftazidime/tazobactam) and group B (treatment with antipseudomonal penicillin or cephalosporins).
Results: We enrolled 77 patients, 56 and 21 in groups A and B, respectively. The two groups were homogeneous for age, sex, and biochemical and clinical characteristics at admission. All-cause in-hospital mortality was 17/56 (30.4%) and 3/21 (14.3%) in groups A and B, respectively (p > 0.1). In group A, in-hospital BSI-related mortality was 23.2% (13/56), while it was 14.3% (3/21) in group B (p > 0.1). After multivariate analysis, only the PITT score represented a risk factor for BSI-related mortality (OR 2.917, 95% CI 1.381-6.163).
Conclusions: Both all-cause and BSI-related mortality were comparable between the two groups. Treatment with carbapenem or ceftazidime/avibactam did not represent a protective factor for mortality in wild-type P. aeruginosa BSI.
背景:铜绿假单胞菌是细菌性疾病中最令人担忧的一种,即使它显示出野生型的药敏模式。2020 年,EUCAST 重新考虑了抗生素图谱的解释,将 "I "从 "中等 "改为 "敏感,暴露增加",这可能会对抗生素处方产生重大影响。本研究旨在评估使用抗假青霉素或头孢菌素与碳青霉烯类和头孢唑肟/阿维巴坦治疗的铜绿假单胞菌血流感染患者的死亡率:这是一项回顾性观察研究。方法:这是一项回顾性观察研究,本院收治的所有铜绿假单胞菌血流感染患者均被纳入研究范围。排除标准如下:病情极其危重、年龄:我们共招募了 77 名患者,A 组和 B 组分别有 56 人和 21 人。两组患者的年龄、性别、入院时的生化和临床特征相同。A 组和 B 组的全因院内死亡率分别为 17/56(30.4%)和 3/21(14.3%)(P > 0.1)。在 A 组,院内 BSI 相关死亡率为 23.2%(13/56),而在 B 组为 14.3%(3/21)(P > 0.1)。经过多变量分析,只有 PITT 评分是 BSI 相关死亡率的风险因素(OR 2.917,95% CI 1.381-6.163):结论:两组患者的全因死亡率和 BSI 相关死亡率相当。使用碳青霉烯类或头孢他啶/阿维巴坦治疗并不是野生型铜绿假单胞菌BSI死亡率的保护因素。
{"title":"Bloodstream Infections Due to Wild-Type <i>Pseudomonas aeruginosa</i>: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes.","authors":"Carlo Pallotto, Andrea Tommasi, Elisabetta Svizzeretto, Giovanni Genga, Giulia Gamboni, Anna Gidari, Daniela Francisci","doi":"10.3390/idr16050064","DOIUrl":"10.3390/idr16050064","url":null,"abstract":"<p><strong>Background: </strong><i>Pseudomonas aeruginosa</i> is one of the major concerns among bacterial diseases even when it shows a wild-type susceptibility pattern. In 2020, EUCAST reconsidered antibiogram interpretation shifting \"I\" from \"intermediate\" to \"sensible, increased exposure\" with possible significant impact on antibiotic prescription. The aim of this study was to evaluate mortality in patients with <i>P. aeruginosa</i> bloodstream infections treated with antipseudomonal penicillins or cephalosporins vs. carbapenems and ceftazidime/avibactam.</p><p><strong>Methods: </strong>This is a retrospective observational study. All the patients with a bloodstream infection due to <i>P. aeruginosa</i> admitted to our hospital were enrolled. Exclusion criteria were as follows: extremely critical conditions, age <18 years, pregnancy, isolation of a strain non-susceptible to piperacillin/tazobactam and antipseudomonal cephalosporins. Patients were divided into group A (treatment with carbapenems or ceftazidime/tazobactam) and group B (treatment with antipseudomonal penicillin or cephalosporins).</p><p><strong>Results: </strong>We enrolled 77 patients, 56 and 21 in groups A and B, respectively. The two groups were homogeneous for age, sex, and biochemical and clinical characteristics at admission. All-cause in-hospital mortality was 17/56 (30.4%) and 3/21 (14.3%) in groups A and B, respectively (<i>p</i> > 0.1). In group A, in-hospital BSI-related mortality was 23.2% (13/56), while it was 14.3% (3/21) in group B (<i>p</i> > 0.1). After multivariate analysis, only the PITT score represented a risk factor for BSI-related mortality (OR 2.917, 95% CI 1.381-6.163).</p><p><strong>Conclusions: </strong>Both all-cause and BSI-related mortality were comparable between the two groups. Treatment with carbapenem or ceftazidime/avibactam did not represent a protective factor for mortality in wild-type <i>P. aeruginosa</i> BSI.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"828-835"},"PeriodicalIF":3.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charlotte Birner, Patricia Mester, Gerhard Liebisch, Marcus Höring, Stephan Schmid, Martina Müller, Vlad Pavel, Christa Buechler
Critical illness causes disturbances in lipid metabolism. Here, we investigated the levels of apolipoprotein A-IV (apoA-IV), a regulator of triglyceride and cholesterol metabolism, in human sepsis. ApoA-IV (analyzed in 156 patients with systemic inflammatory response syndrome (SIRS)/sepsis) and cholesteryl ester (CE) (analyzed in 121 of these patients) were lower in patients compared to 43 healthy controls. In contrast, triglyceride (TG) levels were elevated in patients. ApoA-IV levels in plasma of the patients did not correlate with these lipids. Patients with SIRS, sepsis or septic shock had comparable apoA-IV, TG, CE and free cholesterol (FC) levels. Patients on dialysis had significantly lower CE levels, whereas apoA-IV levels did not change much. CE levels were elevated in patients with viral sepsis due to SARS-CoV-2 infection in comparison to SIRS/sepsis patients not infected by this virus. CE levels correlated negatively with procalcitonin, interleukin-6 and bilirubin, while TGs were positively associated with bilirubin and C-reactive protein. ApoA-IV, TG, CE and FC levels were not associated with bacterial infection or survival. In conclusion, this analysis suggests that CE levels decline in sepsis-related renal failure and also shows that plasma apoA-IV and CE levels are early biomarkers of sepsis.
危重病会导致脂质代谢紊乱。在这里,我们研究了人类败血症中载脂蛋白 A-IV(载脂蛋白 A-IV)的水平,载脂蛋白 A-IV是甘油三酯和胆固醇代谢的调节因子。与 43 名健康对照组相比,患者的载脂蛋白 A-IV(分析对象为 156 名全身炎症反应综合征(SIRS)/败血症患者)和胆固醇酯(分析对象为其中的 121 名患者)水平较低。相比之下,患者的甘油三酯(TG)水平升高。患者血浆中载脂蛋白 A-IV 的水平与这些血脂没有相关性。SIRS、败血症或脓毒性休克患者的载脂蛋白A-IV、TG、CE和游离胆固醇(FC)水平相当。透析患者的 CE 水平明显较低,而载脂蛋白 A-IV 水平变化不大。与未感染SARS-CoV-2病毒的SIRS/败血症患者相比,感染SARS-CoV-2的病毒性败血症患者的CE水平升高。CE 水平与降钙素原、白细胞介素-6 和胆红素呈负相关,而 TG 与胆红素和 C 反应蛋白呈正相关。载脂蛋白 A-IV、TG、CE 和 FC 水平与细菌感染或存活率无关。总之,这项分析表明,脓毒症相关肾衰竭时 CE 水平会下降,同时还表明血浆载脂蛋白 A-IV 和 CE 水平是脓毒症的早期生物标志物。
{"title":"Lipid Metabolism Disorders as Diagnostic Biosignatures in Sepsis.","authors":"Charlotte Birner, Patricia Mester, Gerhard Liebisch, Marcus Höring, Stephan Schmid, Martina Müller, Vlad Pavel, Christa Buechler","doi":"10.3390/idr16050062","DOIUrl":"10.3390/idr16050062","url":null,"abstract":"<p><p>Critical illness causes disturbances in lipid metabolism. Here, we investigated the levels of apolipoprotein A-IV (apoA-IV), a regulator of triglyceride and cholesterol metabolism, in human sepsis. ApoA-IV (analyzed in 156 patients with systemic inflammatory response syndrome (SIRS)/sepsis) and cholesteryl ester (CE) (analyzed in 121 of these patients) were lower in patients compared to 43 healthy controls. In contrast, triglyceride (TG) levels were elevated in patients. ApoA-IV levels in plasma of the patients did not correlate with these lipids. Patients with SIRS, sepsis or septic shock had comparable apoA-IV, TG, CE and free cholesterol (FC) levels. Patients on dialysis had significantly lower CE levels, whereas apoA-IV levels did not change much. CE levels were elevated in patients with viral sepsis due to SARS-CoV-2 infection in comparison to SIRS/sepsis patients not infected by this virus. CE levels correlated negatively with procalcitonin, interleukin-6 and bilirubin, while TGs were positively associated with bilirubin and C-reactive protein. ApoA-IV, TG, CE and FC levels were not associated with bacterial infection or survival. In conclusion, this analysis suggests that CE levels decline in sepsis-related renal failure and also shows that plasma apoA-IV and CE levels are early biomarkers of sepsis.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"806-819"},"PeriodicalIF":3.4,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Petia Genova-Kalou, Yordan Hodzhev, Ilia Tsachev, Roman Pepovich, Stefan Panaiotov, Veselin Dobrinov, Stefka Krumova, Betina Boneva-Marutsova, Borislava Chakarova, Keytlin Todorova, Konstantin Simeonov, Magdalena Baymakova, Pierre-Edouard Fournier
The aim of this study was to assess the prevalence of Coxiella burnetii infection among veterinary medicine students from two Bulgarian Universities, located in Sofia and Stara Zagora. Blood samples were collected from a total of 185 veterinary students for the detection of C. burnetii phase II antibodies and presence of DNA using an enzyme-linked immunosorbent assay (ELISA) and end-point PCR test. Out of all samples, 29.7% were positive for at least one C. burnetii phase II antibody marker or by the result of the PCR test. Veterinary students from Stara Zagora showed a significantly high seropositivity for Q fever (33.6%), as compared to the students in Sofia (23%; p < 0.05). Evidence of recent exposure with detection of anti-C. burnetii phase II IgM (+) antibodies was observed in 14.6% of the students under study. Seroprevalence among students in Stara Zagora was higher (15.3%). Anti-C. burnetii phase II IgG antibodies were detected in 21.6% of examined samples. Our study revealed a higher seropositivity among the male students (32.8%) as compared to females (16.0%; p < 0.05). The end-point PCR assay detected 5.9% blood samples as positive. The relative risk (RR) of Q fever exposure for male students was 40.7%, whereas it was 24.6% in females (p < 0.05). The findings from this study indicate that the C. burnetii infection is widely distributed amongst veterinary students in Bulgaria. This study emphasizes the need for improved safety protocols and infection control measures in veterinary training programs.
{"title":"First Insight into the Prevalence of <i>Coxiella burnetii</i> Infection among Veterinary Medicine Students in Bulgaria.","authors":"Petia Genova-Kalou, Yordan Hodzhev, Ilia Tsachev, Roman Pepovich, Stefan Panaiotov, Veselin Dobrinov, Stefka Krumova, Betina Boneva-Marutsova, Borislava Chakarova, Keytlin Todorova, Konstantin Simeonov, Magdalena Baymakova, Pierre-Edouard Fournier","doi":"10.3390/idr16050061","DOIUrl":"10.3390/idr16050061","url":null,"abstract":"<p><p>The aim of this study was to assess the prevalence of <i>Coxiella burnetii</i> infection among veterinary medicine students from two Bulgarian Universities, located in Sofia and Stara Zagora. Blood samples were collected from a total of 185 veterinary students for the detection of <i>C. burnetii</i> phase II antibodies and presence of DNA using an enzyme-linked immunosorbent assay (ELISA) and end-point PCR test. Out of all samples, 29.7% were positive for at least one <i>C. burnetii</i> phase II antibody marker or by the result of the PCR test. Veterinary students from Stara Zagora showed a significantly high seropositivity for Q fever (33.6%), as compared to the students in Sofia (23%; <i>p</i> < 0.05). Evidence of recent exposure with detection of anti-<i>C. burnetii</i> phase II IgM (+) antibodies was observed in 14.6% of the students under study. Seroprevalence among students in Stara Zagora was higher (15.3%). Anti-<i>C. burnetii</i> phase II IgG antibodies were detected in 21.6% of examined samples. Our study revealed a higher seropositivity among the male students (32.8%) as compared to females (16.0%; <i>p</i> < 0.05). The end-point PCR assay detected 5.9% blood samples as positive. The relative risk (RR) of Q fever exposure for male students was 40.7%, whereas it was 24.6% in females (<i>p</i> < 0.05). The findings from this study indicate that the <i>C. burnetii</i> infection is widely distributed amongst veterinary students in Bulgaria. This study emphasizes the need for improved safety protocols and infection control measures in veterinary training programs.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"794-805"},"PeriodicalIF":3.4,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
COVID-19 and influenza are highly contagious respiratory viral diseases and priority global public health concerns. We conducted a retrospective observational study of COVID-19 and/or influenza hospitalized cases, during 2023. We identified 170 influenza cases, 150 COVID-19 cases and 3 co-infections. Overall, 29.10% of patients had at least one COVID-19 vaccine dose and 4.6% received the seasonal Flu vaccine. The demographic data found older patients in the COVID-19 group and a higher index of the comorbidities, mainly due to chronic heart diseases, hypertension, and diabetes. Fever, chills, and rhinorrhea were more frequently related to influenza, while cough was prevalent in COVID-19. Antibiotics were more used in influenza than COVID-19, either pre-hospital or in-hospital. The mortality rate within the first 30 days from the onset of the respiratory infection was higher in influenza compared to COVID-19. We concluded that the COVID-19 clinical picture in hospitalized patients is changing to influenza-like symptoms. The evolution is variable, related to chronic comorbidities, but influenza had more frequent severe forms. All through 2023, due to poor vaccination rates, COVID-19 and influenza have continued to cause numerous hospitalizations, and a new strategy for efficient vaccinations is required.
{"title":"Comparative Epidemiological and Clinical Outcomes on COVID-19 and Seasonal Influenza Hospitalized Patients during 2023.","authors":"Constantin-Marinel Vlase, Mariana Stuparu Cretu, Mihaela-Camelia Vasile, George-Cosmin Popovici, Manuela Arbune","doi":"10.3390/idr16050060","DOIUrl":"10.3390/idr16050060","url":null,"abstract":"<p><p>COVID-19 and influenza are highly contagious respiratory viral diseases and priority global public health concerns. We conducted a retrospective observational study of COVID-19 and/or influenza hospitalized cases, during 2023. We identified 170 influenza cases, 150 COVID-19 cases and 3 co-infections. Overall, 29.10% of patients had at least one COVID-19 vaccine dose and 4.6% received the seasonal Flu vaccine. The demographic data found older patients in the COVID-19 group and a higher index of the comorbidities, mainly due to chronic heart diseases, hypertension, and diabetes. Fever, chills, and rhinorrhea were more frequently related to influenza, while cough was prevalent in COVID-19. Antibiotics were more used in influenza than COVID-19, either pre-hospital or in-hospital. The mortality rate within the first 30 days from the onset of the respiratory infection was higher in influenza compared to COVID-19. We concluded that the COVID-19 clinical picture in hospitalized patients is changing to influenza-like symptoms. The evolution is variable, related to chronic comorbidities, but influenza had more frequent severe forms. All through 2023, due to poor vaccination rates, COVID-19 and influenza have continued to cause numerous hospitalizations, and a new strategy for efficient vaccinations is required.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"783-793"},"PeriodicalIF":3.4,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jawaher Alguraini, Mohamed T S Saleem, Nahed N Mahrous, Abbas Shamsan, Fatima Zia Zaidi, Ohoud S Alhumaidan, Yahya F Jamous
Objective: This cross-sectional-survey-based study aimed to investigate the severity of side-effects from Coronavirus disease (COVID-19) mRNA (Pfizer, Moderna), viral vector DNA (Oxford-AstraZeneca, J&J/Janssen), inactivated virus (Sinopharm, Sinovac), and other vaccines among healthcare workers (HCWs) in Saudi Arabia, focusing on their impact on work attendance.
Methods: A total of 894 HCWs residing in Saudi Arabia participated in this study from March 2023 to May 2023. Participants completed an online questionnaire assessing demographic information, vaccination status, comorbidities, vaccine side-effects, and missed work information after vaccination. Descriptive statistics and chi-square tests were used for data analysis.
Results: The majority of participants were female (83.7%) and aged 25-34 years (42.8%). Most participants were predominantly vaccinated with mRNA vaccines. Common side-effects included pain at the injection site, fatigue, fever, and chills. However, no significant association was found between vaccine type, side-effects, and work absenteeism. While demographic factors such as age and healthcare profession did not influence work absenteeism, variations were observed among different racial groups.
Conclusion: COVID-19 vaccination among HCWs in Saudi Arabia is associated with common side-effects, but their impact on work attendance is not significant. Understanding these implications can inform strategies to support the healthcare workforce and mitigate the impact on patient care and staffing during the ongoing COVID-19 pandemic.
{"title":"The Impact of COVID-19 Vaccination Side-Effects on Work Attendance among Saudi Healthcare Workers.","authors":"Jawaher Alguraini, Mohamed T S Saleem, Nahed N Mahrous, Abbas Shamsan, Fatima Zia Zaidi, Ohoud S Alhumaidan, Yahya F Jamous","doi":"10.3390/idr16040059","DOIUrl":"10.3390/idr16040059","url":null,"abstract":"<p><strong>Objective: </strong>This cross-sectional-survey-based study aimed to investigate the severity of side-effects from Coronavirus disease (COVID-19) mRNA (Pfizer, Moderna), viral vector DNA (Oxford-AstraZeneca, J&J/Janssen), inactivated virus (Sinopharm, Sinovac), and other vaccines among healthcare workers (HCWs) in Saudi Arabia, focusing on their impact on work attendance.</p><p><strong>Methods: </strong>A total of 894 HCWs residing in Saudi Arabia participated in this study from March 2023 to May 2023. Participants completed an online questionnaire assessing demographic information, vaccination status, comorbidities, vaccine side-effects, and missed work information after vaccination. Descriptive statistics and chi-square tests were used for data analysis.</p><p><strong>Results: </strong>The majority of participants were female (83.7%) and aged 25-34 years (42.8%). Most participants were predominantly vaccinated with mRNA vaccines. Common side-effects included pain at the injection site, fatigue, fever, and chills. However, no significant association was found between vaccine type, side-effects, and work absenteeism. While demographic factors such as age and healthcare profession did not influence work absenteeism, variations were observed among different racial groups.</p><p><strong>Conclusion: </strong>COVID-19 vaccination among HCWs in Saudi Arabia is associated with common side-effects, but their impact on work attendance is not significant. Understanding these implications can inform strategies to support the healthcare workforce and mitigate the impact on patient care and staffing during the ongoing COVID-19 pandemic.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 4","pages":"770-782"},"PeriodicalIF":3.4,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hemophagocytic lymphohistiocytosis (HLH) is a serious haematologic condition that can be related to various diseases, including tuberculosis (TB). The patient is a previously healthy 26-year-old man, originally from western Africa, admitted to hospital for fever and weight loss. Given the results of a computed tomography (CT) scan, ocular examination and microbiologic tests, miliary TB with pulmonary, lymph nodal and ocular involvement was diagnosed. Following the introduction of antitubercular treatment (ATT), an increase in inflammation indexes and severe pancytopenia were observed; at this point, the patient presented with six of the eight diagnostic criteria for HLH, and a diagnosis of HLH secondary to TB was raised. Therefore, HLH treatment with a high dose of dexamethasone was started, with a good clinical response. We performed a literature review of TB-related HLH, which shows a high mortality rate. ATT is necessary to ensure patient survival to remove the antigenic driver. Our patient developed HLH after the initiation of ATT as a paradoxical reaction, which may be linked to the release of antigens due to the bactericidal effect of ATT.
嗜血细胞淋巴组织细胞增多症(HLH)是一种严重的血液病,可能与包括结核病(TB)在内的多种疾病有关。患者是一名 26 岁的男性,原籍非洲西部,因发热和体重减轻入院。根据计算机断层扫描(CT)、眼部检查和微生物检验的结果,诊断为肺部、淋巴结和眼部受累的粟粒性肺结核。在接受抗结核治疗(ATT)后,观察到炎症指数升高和严重的全血细胞减少;此时,患者符合 HLH 八项诊断标准中的六项,因此提出了继发于肺结核的 HLH 诊断。因此,开始使用大剂量地塞米松治疗 HLH,临床反应良好。我们对肺结核相关的 HLH 进行了文献回顾,结果显示死亡率很高。为确保患者存活,有必要进行 ATT,以去除抗原驱动因素。我们的患者在开始 ATT 后出现 HLH,这是一种矛盾反应,可能与 ATT 的杀菌作用导致抗原释放有关。
{"title":"Hemophagocytic Lymphohistiocytosis and Miliary Tuberculosis in an Apparently Immunocompetent Patient: A Case Report.","authors":"Filippo Ducci, Francesca Mariotti, Jessica Mencarini, Claudio Fabbri, Alessandra Francesca Manunta, Daniela Messeri, Paola Parronchi, Pierluigi Blanc, Alessandro Bartoloni","doi":"10.3390/idr16040058","DOIUrl":"10.3390/idr16040058","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a serious haematologic condition that can be related to various diseases, including tuberculosis (TB). The patient is a previously healthy 26-year-old man, originally from western Africa, admitted to hospital for fever and weight loss. Given the results of a computed tomography (CT) scan, ocular examination and microbiologic tests, miliary TB with pulmonary, lymph nodal and ocular involvement was diagnosed. Following the introduction of antitubercular treatment (ATT), an increase in inflammation indexes and severe pancytopenia were observed; at this point, the patient presented with six of the eight diagnostic criteria for HLH, and a diagnosis of HLH secondary to TB was raised. Therefore, HLH treatment with a high dose of dexamethasone was started, with a good clinical response. We performed a literature review of TB-related HLH, which shows a high mortality rate. ATT is necessary to ensure patient survival to remove the antigenic driver. Our patient developed HLH after the initiation of ATT as a paradoxical reaction, which may be linked to the release of antigens due to the bactericidal effect of ATT.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 4","pages":"763-769"},"PeriodicalIF":3.4,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}